NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.
BACKGROUND
Ovarian cancer is the leading cause of death among gynecological cancers. Cisplatin is one of the most effective anticancer drugs used in the treatment of ovarian cancer. Development of resistance to cisplatin limits its therapeutic use. Most of the anticancer drugs, including cisplatin, are believed to kill cancer cells by inducing apoptosis and a defect in apoptotic signaling can contribute to drug resistance. The tumor suppressor protein p53 plays a critical role in DNA damage-induced apoptosis. During a yeast-based drug screening, NSC109268 was identified to enhance cellular sensitivity to cisplatin. The objective of the present study is to determine if p53 is responsible for cisplatin sensitization by NSC109268.


RESULTS
NSC109268 enhanced sensitivity of ovarian cancer 2008 cells and its cisplatin resistant counterpart 2008/C13* cells which express wild-type p53. The potentiation of cisplatin sensitivity by NSC109268 was greater in 2008/C13* cells compared to 2008 cells. Cisplatin caused a concentration-dependent increase in p53 in 2008 and 2008/C13* cells, and the induction of p53 correlated with cisplatin-induced apoptosis as determined by the cleavage of PARP. NSC109268 alone had no effect on p53 but it enhanced p53 level in response to cisplatin. Knockdown of p53 by siRNA, however, did not attenuate cell death in response to cisplatin or combination of NSC109268 and cisplatin.


CONCLUSIONS
These results demonstrate that NSC109268 enhances sensitivity of ovarian cancer 2008 cells to cisplatin independent of p53.
Shankar
Eswar
E
Department of Molecular Biology and Immunology, University of North Texas, Health Science Center, Fort Worth, Texas, USA. alakananda.basu@unthsc.edu.
Basu
Chandreyi
C
Adkins
Brett
B
Siede
Wolfram
W
Basu
Alakananda
A
J Clin Oncol. 2000 Dec 1;18(23):3936-45
11099323
Cancer. 1994 Apr 15;73(8):2013-26
8156506
Nat Rev Cancer. 2009 Oct;9(10):714-23
19730431
Hum Cell. 2001 Sep;14(3):165-71
11774736
Cancer Chemother Pharmacol. 2010 Oct;66(5):945-52
20101404
Nat Rev Drug Discov. 2008 Dec;7(12):979-87
19043449
Br J Cancer. 1997;75(2):230-5
9010031
Biochemistry. 1999 Apr 6;38(14):4245-51
10194341
Cancer Res. 1996 Feb 15;56(4):689-93
8630996
Cell Growth Differ. 1996 Nov;7(11):1507-12
8930400
Nat Rev Cancer. 2002 Aug;2(8):594-604
12154352
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302
12370430
Oncogene. 2003 Oct 20;22(47):7265-79
14576837
J Biol Chem. 1990 May 25;265(15):8451-7
2341390
Oncogene. 2000 Jun 29;19(28):3138-45
10918568
Mol Pharmacol. 2000 Mar;57(3):503-11
10692490
Mol Cancer Ther. 2002 Aug;1(10):861-7
12492119
Biochem Biophys Res Commun. 2004 Apr 16;316(4):1002-8
15044084
J Biol Chem. 1990 Mar 5;265(7):3623-7
2303468
Clin Cancer Res. 2004 Oct 1;10(19):6744-9
15475465
Curr Opin Mol Ther. 1999 Aug;1(4):500-9
11713766
Cell Death Differ. 2007 Apr;14(4):851-60
17186022
Science. 1985 Oct 25;230(4724):412-7
4048939
Br J Cancer. 1997;76(4):474-9
9275024
Hum Mutat. 2003 Mar;21(3):285-91
12619114
Biochem Biophys Res Commun. 2001 May 18;283(4):732-7
11350044
Biochem Pharmacol. 2004 Mar 15;67(6):1139-51
15006550
Nat Rev Cancer. 2007 Aug;7(8):573-84
17625587
J Virol. 1993 Jun;67(6):3111-7
8388491
Int J Cancer. 1995 Aug 9;62(4):457-60
7635571
Clin Cancer Res. 2001 Oct;7(10):2984-97
11595686
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
15789122
Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23
15607932
Oncogene. 2007 May 3;26(20):2860-72
17072341
Nature. 2000 Nov 16;408(6810):307-10
11099028
Tumori. 2009 Jul-Aug;95(4):409-21
19856649
Oncol Res. 1999;11(3):153-9
10527075